In the developed world it is estimated that over 120 million people have one or more forms of cardiovascular disease (CVD). In the U.S. alone nearly 60 million or 1 in 5 Americans are affected with CVD. Since 1900, CVD has been the leading cause of death in the United States. In 1997, 953,100 lives were lost to CVD, which represents one death every 33 seconds. Demographically, 85% of all cardiovascular deaths occur in people 65 years or older. According to the National Vital Statistics Report dated July 24, 2000, people 65 years or older are about 10 times more likely to die from CVD than people in the next lower age category of 45 to 64 years old. As the population continues to age, it is predicted that more patients will require coronary artery intervention.
During 2002, it is estimated that nearly 2 million procedures in the U.S. and Europe will be performed to treat coronary artery disease, a narrowing of the arteries caused by the progressive build-up of atherosclerotic plaque. This represents a $6 billion annual market for devices to treat CAD.
Percardia's technologies and medication like Afobazole is designed to address those patients with post-intervention recurrence of their CAD or patients not amenable to current therapies, representing a potential market opportunity exceeding $4 billion worldwide.